A case report of multiple bilateral breast metastases after colorectal cancer

Arnaout, Khaled; Hawa, Nouran; Agha, Sarab; Kadoura, Lama; Aloulou, Marwa; Ayoub, Kusay

doi:10.1016/j.ijscr.2021.105759

Cited by 7 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although literature reported some rare causes of metastasis to breast, such as contralateral breast, ovary, lung, stomach, leukemia, melanoma, and lymphoma; colon metastasis to breast was even more rare [14][15][16]. As far as we know, there are no more than 30 cases of colon cancer metastasis to breast worldwide [13,17,18]. Researchers' statistical analysis of those cases revealed that the average time form colorectal cancer diagnosis to breast metastasis was 21 months, and the longest transfer time to breast was 7 years so far [13].…”

Section: Discussionmentioning

confidence: 99%

“…CT: Computed tomography; XELOX: Oxaliplatin 130 mg/m 2 on day 1 plus capecitabine 1000 mg/m 2 twice daily on days 1 to 14 every 3 weeks for 18 weeks; CA 724: Carbohydrate antigen 724; AJCC: American Joint Committee on Cancer; KRAS: Kirsten rat sarcoma viral oncogene homolog; NRAS: Neuroblastoma RAS viral (v-ras) oncogene homolog; BRAF: V-raf murine sarcoma viral oncogene homolog B1; CK-pan: Cytokeratin-pan; CK-20: Cytokeratin-20; CK-7: Cytokeratin-7; CEA: Carcinoembryonic antigen; Ki-67: Marker of proliferation Ki-67; P120: P120 catenin; CDX-2: Caudal-type homeobox protein 2; E-cad: E-cadherin; GATA3: GATA binding protein 3; GCDFP-15: Gross cystic disease fluid protein 15; HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor; CDK5/6: Cyclin-dependent kinase 5/6; PET/CT: Positron emission tomography computed tomography; SUVmax: Maximum standardized uptake; 18 F-FDG: 18 Fluorine-fluorodeoxyglucose; RECIST: Response Evaluation Criteria in Solid Tumors.…”

Section: Abbreviationsmentioning

confidence: 99%

“…The maximum standardized uptake (SUVmax) of 18F-FDG was 5.3. B After the radical resection of colon cancer,18 F-FDG was increased at the anastomotic site and distal intestine with a SUVmax value of 4.4. Tracer distribution was enhanced at transverse colon, splenic flexure of colon, and rectum.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Breast metastasis of signet ring cell carcinoma from the colon: a case report

Wang

Zhang

2022

World J Surg Onc

View full text Add to dashboard Cite

Background Colon cancer is one of the most common diagnosed malignancies. Despite the use of surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and other comprehensive treatments, distant metastasis is still one of the main causes for dying of colon cancer. The common metastatic site of colon cancer is the liver, lung, and bone. In this article, we report a rare case of breast metastasis of signet ring cell carcinoma from the colon. Case presentation A 44-year-old woman was diagnosed with colon cancer and received a radical surgery of colon cancer in 2019. Combined with postoperative pathological and computed tomography (CT) images, a diagnosis of cT3N2M0 mucinous adenocarcinoma of colon (according to AJCC cancer staging manual, Version 8) was established. Adjuvant chemotherapy (XELOX: oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 18 weeks) was performed followed by surgical resection. Fourteen months later, the patient underwent mastectomy for breast mass, which was diagnosed pathologically as metastasis of signet ring cell carcinoma from the colon. XELOX chemotherapy regimen (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 24 weeks) combined with bevacizumab (7.5 mg/kg on day 1) was used after the mastectomy. The patient had stable disease according to her last examination (RECIST criteria). Conclusion It is rare to find a report of a patient of colon cancer that metastasizes to breast. We hope to increase treatment experience for patients with this rare metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Abbreviationsmentioning

confidence: 99%

See 1 more Smart Citation

Breast metastasis of signet ring cell carcinoma from the colon: a case report

Wang

Zhang

2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Although literature reported some rare regions metastasis to breast, such as contralateral breast, ovary, lung, stomach, leukemia, melanoma and lymphoma, colon metastasis to breast was even more rarely [13][14][15]. As far as we know, there are no more than 30 cases of colon cancer metastasis to breast worldwide [12,16,17]. Researchers' statistical analysis of those cases revealed that the average time form colorectal cancer diagnosis to breast metastasis was 21 months and the longest transfer time to breast was 7 years so far [12].…”

Section: Discussionmentioning

confidence: 99%

Breast Metastasis Of Signet Ring Cell Carcinoma From The Colon: A Case Report

Wang

2022

Preprint

View full text Add to dashboard Cite

Background: Colon cancer is one of the most common diagnosed malignancies. Although the use of surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy and other comprehensive treatment, distant metastasis is still one of the main causes for dying of colon cancer. The common metastatic site of colon cancer is liver, lung and bone. In this article, we report a rare case of breast metastasis of signet ring cell carcinoma from the colon. Case Presentation: A 44-year-old woman was diagnosed with colon cancer and received a radical surgery of colon cancer in 2019. Combined with postoperative pathological and CT images, a diagnosis of cT3N2M0 mucinous adenocarcinoma of colon (according to AJCC cancer staging manual, Version 8) was established. Adjuvant chemotherapy (XELOX: oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 18 weeks) was performed followed by surgical resection. 14 months later, the patient received mastectomy for breast mass, which was diagnosed pathologically as metastasis of signet ring cell carcinoma from the colon. XELOX chemotherapy regimen (oxaliplatin 130 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 24 weeks) combined with bevacizumab (7.5mg/kg on day 1) were used after the mastectomy. The patient was stable disease according to her last examination (RECIST criteria).Conclusion: It is rare to report a patient diagnosed with colon cancer which metastasis to breast. We hope to increase treatment experience for patients with this rare metastasis.

show abstract

“…Breast metastasis is rare, with an incidence of 0.5%–3%[ 3 ], and is especially rare from colon carcinoma. Since the first case reported in 1976[ 4 ], only no more than 30 cases have been reported[ 5 , 6 ]. Hsieh and Hsu[ 7 ] summarized 45 cases that were previously reported, and we found that about 60 studies have reported this rare case so far by searching the literature in the Reference Citation Analysis ( ) database, PubMed, and Embase.…”

Section: Introductionmentioning

confidence: 99%

Successful treatment of breast metastasis from primary transverse colon cancer: A case report

Jiao¹,

Xing²,

Zhai³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND The incidence of colon cancer is increasing worldwide. Treatments for colon cancer include surgery and surgery combined with chemotherapy and radiotherapy, but the median survival rate is still poor. Colon cancer most commonly metastasizes to the lymph nodes, lungs, liver, peritoneum, and brain, but breast metastasis is rare. There is no agreement on its treatment. CASE SUMMARY A 23-year-old woman was admitted to our hospital for further treatment with a history of acute abdominal pain, nausea, and vomiting. Her physical examination and computed tomography scan revealed an abdominal tumor. Transverse colectomy was successfully performed. Histopathological examination revealed that the tumor was a mucosecretory adenocarcinoma with signet ring cells. The patient inadvertently found a mass in the outer upper quadrant of the right breast after four cycles of XELOX chemotherapy [oxaliplatin 130 mg/m 2 , d1, intravenous (iv) drip for 2 h; capecitabine 1000 mg/m 2 , po, bid, d1–d14]. After discussion with the patient, we performed a lumpectomy and frozen biopsy. The latter revealed that the breast tumor was intestinal metastasis. Genetic testing showed wild-type RAS and BRAF . So we replaced the original chemotherapy with FOLFIRI [irinotecan 180 mg/m 2 , d1, iv drip for 3–90 min; leucovorin 400 mg/m 2 , d1, iv drip for 2 h; 5-fluorouracil (5-FU) 400 mg/m 2 , d1 and 5-FU 1200 mg/(m 2 d) × 2 d, continuous iv drip for 46–48 h] + cetuximab (500 mg/m 2 , d1, iv drip for 2 h). Serum levels of tumor markers returned to normal after several treatment cycles, and there was no evidence of tumor recurrence or metastasis. CONCLUSION Breast metastasis from colon cancer is rare. Radical breast surgery should be avoided unless needed for palliation. Chemotherapy combined with targeted therapy should be the first choice.

show abstract

A case report of multiple bilateral breast metastases after colorectal cancer

Cited by 7 publications

References 20 publications

Breast metastasis of signet ring cell carcinoma from the colon: a case report

Breast metastasis of signet ring cell carcinoma from the colon: a case report

Breast Metastasis Of Signet Ring Cell Carcinoma From The Colon: A Case Report

Successful treatment of breast metastasis from primary transverse colon cancer: A case report

Contact Info

Product

Resources

About